Sidney Kimmel Comprehensive Cancer Center

New Resource from National Comprehensive Cancer Network Breaks the Silence on Common but Lesser-Known Cause of Cancer Deaths

Retrieved on: 
Thursday, September 7, 2023

PLYMOUTH MEETING, Pa., Sept. 7, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) today announced the publication of a new supportive care patient guideline focused on preventing and treating cancer-associated blood clots, also known as venous thromboembolism (VTE). Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer. Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2

Key Points: 
  • Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • Blood clots are a leading cause of death for people with cancer, second only to the direct effects of the cancer itself.1,2
    Research shows that people with cancer are nine times more likely to experience blood clots than those without cancer.
  • "Cancer is a strong risk factor for developing a blood clot, and thrombosis is the second leading cause of death in patients with cancer.
  • Preventing and treating blood clots is also discussed in several relevant disease-specific NCCN patient guidelines, including for pancreatic cancer, multiple myeloma, and myeloproliferative neoplasms.

Brenus Pharma announces its international Scientific Committee

Retrieved on: 
Wednesday, June 7, 2023

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.

Key Points: 
  • Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee.
  • This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer.
  • The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field:
    Pr François GHIRINGHELLI MD, PhD.
  • Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment.

Break Through Cancer, A New Research Consortium, Names First Class of Scientists Designated as Catalysts for Innovation and Collaboration

Retrieved on: 
Tuesday, April 25, 2023

CAMBRIDGE, Mass., April 25, 2023 /PRNewswire/ -- Break Through Cancer, a foundation designed to find new solutions to some of the most intractable challenges in cancer, has named four individuals as Break Through Cancer Scientists—Neelkanth Bardhan, Sreyashi Basu, Paola A. Guerrero, and Thomas R. Pisanic II. They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.

Key Points: 
  • They are professional scientists who cooperate on and lead projects with the skills, knowledge, and insights to maximize the impact of the cross-institutional collaboration.
  • The Break Through Cancer Scientists were carefully selected based on their expertise in early diagnostics, single cell genomics data and materials science, and specific types of cancer.
  • "These newly named Break Through Cancer Scientists have cultivated stellar reputations and demonstrated outstanding success in working across scientific disciplines to establish a collaborative environment.
  • A Research Group Leader at The University of Texas MD Anderson Cancer Center's Pancreatic Cancer Research Center, Paola leads innovative research on patient-derived models and biospecimens.

Cancer Nutrition Consortium Releases Cookbook to Provide Cancer Patients with Best Nutrition Possible

Retrieved on: 
Monday, January 9, 2023

BOSTON, Jan. 9, 2023 /PRNewswire-PRWeb/ -- Food is one of the basic necessities of life.

Key Points: 
  • Cookbook is a collection of nutrition-focused recipes, based on clinical research, designed to give cancer patients the best nutrition possible while facing challenges during chemotherapy, radiation, and surgical treatments.
  • According to a 2015 study, "The Impact of Cancer Treatment on the Diets & Food Preferences of Patients Receiving Outpatient Treatment" , one of the biggest challenges for people undergoing cancer treatment is getting proper nutrition.
  • Cooking Through Treatment is produced and published by the Cancer Nutrition Consortium (CNC), a non-profit that works to promote and better understand the importance of nutrition for positive medical outcomes for patients during cancer treatment and recovery.
  • The Cancer Nutrition Consortium, Inc. is approved as a tax-exempt, not-for-profit 501(c)(3) corporation organized in the State of Florida.

Think tank’ develops proposals to leverage precision medicine to improve cholangiocarcinoma patient outcomes

Retrieved on: 
Tuesday, October 25, 2022

This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.

Key Points: 
  • This effort, made possible by generous philanthropic donations to the Cholangiocarcinoma Foundation , was the first of its kind in the cholangiocarcinoma (CCA) field.
  • The primary themes precision prevention, early detection, and precision therapeutics reflected areas of urgency and opportunity for improving outcomes for people impacted by CCA.
  • Cholangiocarcinoma is a type of cancer that forms in the slender tubes called bile ducts that carry the digestive fluid bile.
  • Its mission is to find a cure for cholangiocarcinoma (bile duct cancer) and improve the quality of life for patients.

KRAS Kickers Give Cancer the Boot!

Retrieved on: 
Wednesday, September 28, 2022

CHARLOTTE, N.C., Sept. 28, 2022 /PRNewswire/ -- Cancer patient advocates, doctors, researchers, and pharmaceutical industry partners are joining forces during KRAS Kickers Connect conference Sept. 30-Oct. 1 in Charlotte. The in-person and virtual hybrid event features world renowned scientists and patient advocate leaders. KRAS Kickers Connect will be held Friday and Saturday at the Hyatt Centric Charlotte SouthPark, 3100 Apex Dr., Charlotte.

Key Points: 
  • CHARLOTTE, N.C., Sept. 28, 2022 /PRNewswire/ -- Cancer patient advocates, doctors, researchers, and pharmaceutical industry partners are joining forces during KRAS Kickers Connect conference Sept. 30-Oct. 1 in Charlotte.
  • KRAS Kickers Connect will be held Friday and Saturday at the Hyatt Centric Charlotte SouthPark, 3100 Apex Dr., Charlotte.
  • "For decades, KRAS-driven cancers were considered 'undruggable,'" says Terri Conneran, KRAS Kickers Founder and Charlotte lung cancer patient.
  • Conneran, who has been battling lung cancer since 2017, founded KRAS Kickers to create a network for patients and families in search of KRAS information and support.

Amberstone Biosciences Announces Formation of Scientific Advisory Board

Retrieved on: 
Monday, June 27, 2022

LAGUNA HILLS, Calif., June 27, 2022 /PRNewswire/ -- Amberstone Biosciences ( www.amberstonebio.com ), an emerging biotech company with expertise in developing a new generation of cancer therapeutics, is announcing the formation of a scientific advisory board comprised of industry leaders in drug delivery, oncology, immunology and pharmaceutical sciences.

Key Points: 
  • LAGUNA HILLS, Calif., June 27, 2022 /PRNewswire/ -- Amberstone Biosciences ( www.amberstonebio.com ), an emerging biotech company with expertise in developing a new generation of cancer therapeutics, is announcing the formation of a scientific advisory board comprised of industry leaders in drug delivery, oncology, immunology and pharmaceutical sciences.
  • The board will work closely with Amberstone to advance the company's therapeutic programs based on its Tumor Microenvironment Activated Therapeutics (T-MATE) platform.
  • "Each member of our scientific advisory board brings deep expertise in critical areas for drug development," said Dr. George Wu, chief executive officer of Amberstone.
  • The members of the Amberstone board include:
    Robert Langer, ScD, is an institute professor at the Massachusetts Institute of Technology.

Lantern Pharma to Host Virtual KOL Event on Glioblastoma Multiforme (GBM) with Collaborators from Johns Hopkins during Brain Tumor Awareness Month

Retrieved on: 
Thursday, May 12, 2022

The webinar will focus on glioblastoma multiforme (GBM) and the potential of Lantern's drug candidate LP-184 for GBM as well as other brain cancers.

Key Points: 
  • The webinar will focus on glioblastoma multiforme (GBM) and the potential of Lantern's drug candidate LP-184 for GBM as well as other brain cancers.
  • The webcast will feature discussions by two leading experts in GBM and brain cancer treatment and research: John Laterra, M.D., Ph.D. and Matthias Holdhoff, M.D., Ph.D.
  • Dr. Holdhoff completed his residency in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital.
  • Lantern is currently developing four drug candidates and an ADC program across ninedisclosed tumor targets, including two phase 2 programs.

AHN Cancer Institute Becomes One of Country's First Centers to Offer Women Groundbreaking GammaPod Treatment for Early-Stage Breast Cancer

Retrieved on: 
Friday, February 18, 2022

GammaPod is the world's first radiation device specifically designed for the treatment of breast cancer.

Key Points: 
  • GammaPod is the world's first radiation device specifically designed for the treatment of breast cancer.
  • GammaPod is available at only two other centers nationwide, and AHN is the first health system in Pennsylvania to offer the groundbreaking treatment to its patients.
  • Patti was AHN's first patient treated with GammaPod, which is located at AHN Cancer Institute's hub at Allegheny General Hospital.
  • Good candidates for GammaPod treatment include women with early stage breast cancer, ages 50 or older, and those who are eligible for lumpectomy.

Sun Nuclear Corporation and Allegheny Health Network Strengthen Relationship for Standardized Radiation Therapy Quality Assurance

Retrieved on: 
Thursday, December 9, 2021

MELBOURNE, Fla., Dec. 9, 2021 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), announced today that Allegheny Health Network (AHN), a Highmark Health Company, has selected Sun Nuclear as its radiation therapy Quality Assurance (QA) solutions partner.

Key Points: 
  • MELBOURNE, Fla., Dec. 9, 2021 /PRNewswire/ -- Sun Nuclear Corporation (Sun Nuclear), a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), announced today that Allegheny Health Network (AHN), a Highmark Health Company, has selected Sun Nuclear as its radiation therapy Quality Assurance (QA) solutions partner.
  • As a leader in advanced stereotactic treatments, the network uses the SRS MapCHECK array, StereoPHAN device, and MultiMet-WL Cube from Sun Nuclear.
  • "We are pleased to partner with AHN, a network dedicated to excellence in radiation therapy," notes Eric Schloesser, President of Sun Nuclear.
  • Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) provides innovative solutions for Radiation Therapy and Diagnostic Imaging centers.